Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
731
Shown on this page
12
Local recruiting
41
Local phase groups
6
The trial list below is retrieved from the live ClinicalTrials.gov search API for Leukemia. Results on this page are currently sorted by Recently updated.

Filter and sort this condition

These controls apply only within Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 731 matching trials for Leukemia.
Indexed local directory records.

Indexed official records

Open in full search
Conditions
Acute Leukemia, Leukemia
Interventions
TRIAL Web-Based Application
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma
Interventions
Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Inotuzumab ozogamicin, Mercaptopurine, Methotrexate, Pegfilgrastim, Prednisone, Rituximab, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Seattle, Washington
Conditions
Hematological Malignancy, Leukemia, Lymphoid Leukemia, Monocytic Leukemia, Multiple Myeloma, Myeloid Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
Interventions
Behavioral Coaching Intervention, Virtual Exercise Platform
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Leukemia, Minimal Residual Disease, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
Procedure · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Graft-versus-host Disease, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes, Non-hodgkin Lymphoma
Interventions
Busulfan, Clofarabine, Cord Blood Units, Cyclophosphamide, Cyclosporine, Fludarabine, Mycophenolate Mofetil, Tacrolimus, Thiotepa, Total Body Irradiation
Drug · Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 26 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Biphenotypic Acute Leukemia, Burkitt Leukemia, Burkitt Lymphoma, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia With Crisis of Blast Cells, Chronic Myelogenous Leukemia, Accelerated Phase, Leukemia, Lymphoblastic Lymphoma, Lymphoma After Relapse, Myelodysplasia, Other Malignant Hematologic Diseases in Remission
Interventions
Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
0 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
Conditions
Anal Cancer, Bile Duct Cancer, Bladder Cancer, Breast Cancer, Central Nervous System Cancer, Central Nervous System Tumor, Colon Cancer, Duodenal Cancer, Endometrial Cancer, Esophageal Cancer, Familial Adenomatous Polyposis, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Stromal Tumors, Healthy Control, Hypopharyngeal Cancer, Kidney Cancer, Laryngeal Cancer, Leukemia, Lip Cancer, Liver Cancer, Lung Cancer, Lynch Syndrome, Melanoma, Mesothelioma, Multiple Myeloma, Nasal Cavity Cancer, Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Paranasal Sinus Cancer, Penile Cancer, Peritoneal Surface Malignancies, Plasma Cell Dyscrasia, Prostate Cancer, Rectal Cancer, Salivary Gland Cancer, Sarcoma, Skin Cancer, Small Intestine Cancer, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Unknown Primary Tumor, Ureter Cancer, Urethral Cancer, Vaginal Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Conditions
Leukemia
Interventions
Chemotherapy, Placebo, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
53
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 44 more
Conditions
Leukemia
Interventions
Allopurinol, Obinutuzumab, Pirtobrutinib, Valacyclovir, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Blood Cancer, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
Interventions
Palliative Care, Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts

About this Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Leukemia.